阿布昔替尼与度普利尤单抗对特应性皮炎皮肤屏障及蛋白质组的影响比较
本研究将33例中重度特应性皮炎患者随机分为度普利尤单抗组16例和阿布昔替尼组17例,评估基线、4周和12周的皮肤屏障参数及胶带剥离蛋白质组。
要点
- 阿布昔替尼上调皮损区丝聚蛋白-2和兜甲蛋白,度普利尤单抗无此效应。
- 差异蛋白主要涉及神经酰胺代谢、神经生物学和角质形成细胞生物学。
核心结论
- 阿布昔替尼和度普利尤单抗均能有效恢复特应性皮炎皮肤屏障功能,但蛋白质组影响不同。
研究设计与样本
- 随机对照研究,纳入33例中重度特应性皮炎患者,度普利尤单抗组16例,阿布昔替尼组17例。
- 在基线、4周和12周评估临床结局和皮肤屏障参数(经皮水分丢失和含水量)。
- 采集胶带剥离样本进行四维数据独立采集蛋白质组学分析。
主要发现
- 差异表达蛋白主要与神经酰胺代谢、神经生物学和角质形成细胞生物学相关。
- 潜在生物标志物:皮损区精氨酸酶1和蛋白酶体亚基β6型,非皮损区颗粒钙蛋白和磷脂酶D3。
- 阿布昔替尼增强皮损区关键屏障蛋白(丝聚蛋白-2和兜甲蛋白)表达,度普利尤单抗未观察到此效应。
临床怎么用
- 对于关注皮肤屏障恢复的特应性皮炎患者,阿布昔替尼可能更优地降低非皮损区经皮水分丢失并上调屏障蛋白。
局限性
- 队列样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The comparative impact of dupilumab and abrocitinib on skin barrier function and associated proteomics in atopic dermatitis (AD) remains not fully identified. OBJECTIVE: To investigate the effects of dupilumab versus abrocitinib on skin barrier function and proteomic profiles in AD. METHODS: In this study, 33 patients with moderate-to-severe AD were randomized into 2 groups: 16 received dupilumab and 17 received abrocitinib. Clinical outcomes and skin barrier parameters (transepidermal water loss and hydration) were assessed at baseline, 4 weeks, and 12 weeks. Skin tape strips were collected for four-dimensional data-independent acquisition-based proteomics. RESULTS: Both therapies improved skin barrier function, with abrocitinib achieving superior reductions in transepidermal water loss in nonlesional skin (P = .0168). Proteomic analysis revealed differentially expressed proteins predominantly associated with ceramide metabolism, neurobiology, and keratinocyte biology in AD. Key potential biomarkers were identified: arginase 1 and proteasome subunit beta type-6 in lesional skin, alongside grancalcin and phospholipase D3 in nonlesional skin. Abrocitinib enhanced the expression of crucial barrier proteins, such as filaggrin-2 and loricrin, in lesional skin-an effect not observed with dupilumab. LIMITATIONS: The cohort size is small. CONCLUSION: While both abrocitinib and dupilumab effectively restore skin barrier function in AD, they exhibit distinct proteomic impacts.
引用
- Chang JW, Huang X, Jiang W, et al. Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis. J Am Acad Dermatol. 2025. PMID: 40246083. doi:10.1016/j.jaad.2025.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。